Comparisons › PFE / MRK
Pfizer vs Merck: comparing PFE and MRK stock
12-month growth, from 100━ PFE +27.7% ━ MRK +76.9%
| Metric | PFE | MRK |
|---|---|---|
| Price, $ | 29.88 | 146.94 |
| Year to date | +24.0% | +40.6% ● |
| 12 months | +27.7% | +76.9% ● |
| From 52-week high | −5.0% ● | −6.4% |
| vs 200-day average | +11.8% | +15.4% ● |
| P/E | 9.8 | 47.1 |
| Dividend yield | 5.64% ● | 2.27% |
| Revenue growth, YoY | +1.3% | +4.9% ● |
| Operating income growth | +8.5% ● | −62.7% |
| Operating margin | 29.0% ● | 15.1% |
| Gross margin | 74.9% | 76.9% ● |
| Market cap | $170.3B | $362.5B |
| Next earnings | Feb 2, 2027 | Feb 2, 2027 |
● — whose figure is higher, not which is better. Data as of Nov 5, 2026.
Ratings and a detailed chart for each are in the terminal.
Open the terminalFAQ
Which is better to buy: Pfizer or Merck?
We do not advise what to buy. By the numbers: Merck rose more over the year (+76.9%); Pfizer is closer to its 52-week high; Pfizer has the higher operating margin; Merck is growing revenue faster; Pfizer has the lower P/E. How to weigh such signs is covered in «How to analyse a stock».
Can I buy both?
Yes. Many hold several companies in one industry to avoid depending on one. A broad index fund often already holds the largest US companies.
When do they report?
Pfizer — Feb 2, 2027; Merck — Feb 2, 2027.